×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

AstraZeneca's Covid prevention drug meets primary goals in late-stage study

The investigational long-acting antibody therapy called sipavibart showed a 'statistically significant reduction' in symptomatic Covid-19 cases in an immunocompromised patient population, the company said.
Last Updated : 16 May 2024, 06:47 IST

Follow Us :

Comments
ADVERTISEMENT
Published 16 May 2024, 06:47 IST

Follow us on :

Follow Us